9 news items
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update
CGTX
7 May 24
with mild-to-moderate dementia with Lewy bodies (DLB) in the Phase 2 SHIMMER study, exceeding our target. In addition, we are preparing
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer's Disease
CGTX
22 Apr 24
their perspectives on the currently approved immunotherapies for early Alzheimer's disease, including perception of their effectiveness in targeting plaque
Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference
CGTX
2 Apr 24
biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders
Oppenheimer Maintains Outperform on Cognition Therapeutics, Maintains $9 Price Target
CGTX
27 Mar 24
Oppenheimer analyst Jay Olson maintains Cognition Therapeutics (NASDAQ:CGTX) with a Outperform and maintains $9 price target.
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
CGTX
26 Mar 24
measured target engagement in the journal, Translational Neurodegeneration
otg1qgn5bdjnpq7rlroq4pbsb3h59z 242jks2oql9d2
CGTX
15 Mar 24
, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our
9fza7lcyz1l
BSFC
CGTX
EKSO
15 Mar 24
company engaged in the discovery and development of innovative, small-molecule therapeutics targeting age-related degenerative diseases and disorders
suuuxp5qm17t4nuemc0g1gafr9frmtcu0anfrabcoj241euz1l
CGTX
11 Mar 24
in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous
katifrsw2td6ivzsemre
CGTX
6 Mar 24
. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age
- Prev
- 1
- Next